RRC ID 42139
Author Sugiura S, Goshima F, Takakuwa H, Sata T, Nakashima T, Nishiyama Y.
Title Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
Journal Otolaryngol Head Neck Surg
Abstract OBJECTIVE:Attenuated, replication-competent herpes simplex viruses (HSVs) have shown promise as antitumor agents for cancer therapy. In this study, we sought to develop a novel type of oncolytic HSV with more potent antitumor activity for use in localized malignant tumors.
STUDY DESIGN:A new, attenuated multimutated HSV (termed HL) was developed, and then a highly metastatic murine fibrosarcoma cell line, NfSa Y83, was injected into the necks or flanks of immunocompetent C3H mice. The mice were treated with attenuated HSV mutants by intratumoral injection, and antitumor efficacy was assessed by measuring tumor dimensions and overall survival rates.
RESULTS:Treatment with intratumoral injection of HL resulted in marked regression of tumors. In fact, roughly 75% of flank tumors and 50% of neck tumors were completely eradicated.
CONCLUSION:A novel type of attenuated HSV recombinant HL demonstrated a remarkable antitumor efficacy in a localized tumor model in mice.
Volume 130(4)
Pages 470-8
Published 2004-4-1
DOI 10.1016/j.otohns.2004.01.001
PII S0194599804000087
PMID 15100647
MeSH Animals Cancer Vaccines* / genetics Cancer Vaccines* / therapeutic use Cell Line, Tumor Chlorocebus aethiops Female Fibrosarcoma / therapy* Genetic Engineering Herpesvirus 1, Human* / genetics Immunocompetence Injections, Intralesional Mice Mice, Inbred C3H Vaccines, Attenuated / genetics Vaccines, Attenuated / therapeutic use Vero Cells Viral Proteins / genetics Virus Replication Xenograft Model Antitumor Assays
IF 2.341
Times Cited 10
WOS Category OTORHINOLARYNGOLOGY SURGERY
Resource
Human and Animal Cells NFSa Y83(RCB0282)